The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis

Exclusion Criteria

• •Received any topical immunomodulating or immunosuppresive treatment on the lower back two weeks prior, or applied crème/lotion on the lower back 24 hours prior to day 0.
• •Received systemic immunomodulating or immunosuppressive treatment four weeks prior to day 0.
• •Any skin lesions at the area of interest such as nevi, scar tissue or pigment changes.
• •Dermatitis and/or infection.
• •Recent (3 months or less) administration of a live virus vaccine.
• •Women of childbearing potential who are not taking adequate contraception or who are pregnant, plan to become pregnant during the study duration or lactating.
• •Taking part in any other intervention study.
• •Has any other condition which would, in the Investigator's opinion, deem the patient unsuitable for participation in the study (e.g. condition requiring long term or frequent oral steroid use).
• •Presence of any condition or use of any medication which precludes the use of the study drug.
• •Allergy to any of the ingredients in the drug.